ADMA BIOLOGICS, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $25.05M.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $130.19M.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $8.90M.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $23.04M.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for fiscal 2025 was $31.94M.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for fiscal 2024 was $0.00.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for fiscal 2023 was $0.00.
- ADMA BIOLOGICS, INC. payments for repurchase of common stock for fiscal 2012 was $150.00K.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $25.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $187.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $130.19M 10-Q · filed 2026-05-06 | $162.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $8.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $31.94M 10-K · filed 2026-02-25 |
| 2025-09-30 | $23.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $23.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 | |
| 2012-12-31 | $150.00K 10-K · filed 2014-03-28 | |
| 2011-12-31 | $0.00 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |